AIRSUPRA® (albuterol/budesonide) represents a paradigm shift in asthma rescue as the first and only FDA-approved anti-inflammatory rescue inhaler for asthma that is designed to address both ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide ...
AIRSUPRA contains a short-acting beta2-agonist (SABA), to help relax the smooth muscles of the airways, and an inhaled corticosteroid (ICS), to help decrease inflammation in the lungs.2 AIRSUPRA was ...
The Food and Drug Administration approved AstraZeneca and Avillion’s Airsupra (formerly PT027), as an asthma rescue treatment this week. The approval came after the results of the drug’s MANDALA and ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
Findings from a first-of-its-kind virtual trial in pulmonary medicine, conducted at Rutgers and many other institutions, suggest adding an inhaled corticosteroid to rescue therapy could sharply reduce ...
Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...
As asthma symptoms worsen, patients typically rely on short-acting β 2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma ...
WILMINGTON, Del.--(BUSINESS WIRE)--The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favorable benefit risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results